Download the Free Prime PubMed App to your smartphone or tablet.

Available for iPhone or iPad:

Unbound PubMed app for iOS iPhone iPadAlso Available:
Unbound PubMed app for Android

Available for Mac and Windows Desktops and laptops:

Unbound PubMed app for Windows
Did you mean: (Hytrin 10 80)?
(Vytorin 10 80)
97 results
  • Lowering Targeted Atherogenic Lipoprotein Cholesterol Goals for Patients at "Extreme" ASCVD Risk. [Review]
    Curr Diab Rep 2019; 19(12):146Rosenblit PD
  • To review randomized interventional clinical and imaging trials that support lower targeted atherogenic lipoprotein cholesterol goals in "extreme" and "very high" atherosclerotic cardiovascular disease (ASCVD) risk settings. Major atherosclerotic cardiovascular event (MACE) prevention among the highest risk patients with ASCVD requires aggressive management of global risks, including lowering of …
  • Ezetimibe for the prevention of cardiovascular disease and all-cause mortality events. [Meta-Analysis]
    Cochrane Database Syst Rev 2018; 11:CD012502Zhan S, Tang M, … Wu X
  • CONCLUSIONS: Moderate- to high-quality evidence suggests that ezetimibe has modest beneficial effects on the risk of CVD endpoints, primarily driven by a reduction in non-fatal MI and non-fatal stroke, but it has little or no effect on clinical fatal endpoints. The cardiovascular benefit of ezetimibe might involve the reduction of LDL-C, total cholesterol and triglycerides. There is insufficient evidence to determine whether ezetimibe increases the risk of adverse events due to the low and very low quality of the evidence. The evidence for beneficial effects was mainly obtained from individuals with established atherosclerotic cardiovascular disease (ASCVD, predominantly with acute coronary syndrome) administered ezetimibe plus statins. However, there is limited evidence regarding the role of ezetimibe in primary prevention and the effects of ezetimibe monotherapy in the prevention of CVD, and these topics thus requires further investigation.
  • Benefit of Ezetimibe Added to Simvastatin in Reduced Kidney Function. [Randomized Controlled Trial]
    J Am Soc Nephrol 2017; 28(10):3034-3043Stanifer JW, Charytan DM, … Blazing MA
  • Efficacy of statin-based therapies in reducing cardiovascular mortality in individuals with CKD seems to diminish as eGFR declines. The strongest evidence supporting the cardiovascular benefit of statins in individuals with CKD was shown with ezetimibe plus simvastatin versus placebo. However, whether combination therapy or statin alone resulted in cardiovascular benefit is uncertain. Therefore, …
  • Physicians' Experiences as Patients with Statin Side Effects: A Case Series. [Journal Article]
    Drug Saf Case Rep 2017; 4(1):3Koslik HJ, Meskimen AH, Golomb BA
  • Physicians are among those prescribed statins and therefore, subject to potential statin adverse effects (AEs). There is little information on the impact of statin AEs on physicians affected by them. We sought to assess the character and impact of statin AEs occurring in physicians and retired physicians, and to ascertain whether/how personal experience of AEs moderated physicians' attitude towar…
  • Lipid Screening in Childhood and Adolescence for Detection of Familial Hypercholesterolemia: A Systematic Evidence Review for the U.S. Preventive Services Task Force [BOOK]
    Agency for Healthcare Research and Quality (US): Rockville (MD)Lozano P, Henrikson NB, … Whitlock EBOOK
  • CONCLUSIONS: We found no direct evidence of the effect of screening on intermediate or health outcomes. The evidence describing the diagnostic yield of screening for FH in children is minimal. There is good evidence of the effectiveness of statins in reducing LDL-C and TC concentrations in studies up to 2 years long and limited evidence of a statin effect on measures of atherosclerosis. Statins were generally well-tolerated in the short term, although reversible elevations of liver enzymes and/or creatine kinase concentrations were noted in some studies and a decrease in dehydroepiandrosterone sulfate was noted in one study. Bile-acid binding resins were commonly associated with adverse gastrointestinal symptoms and poor palatability. Long-term harms are unknown. Randomized trials of screening for FH in U.S. youth are needed, as are longer-term treatment trials evaluating the benefits and harms of medications in children and adolescents with FH.
New Search Next